Genitourinary Cancers

9 protocols meet the specified criteria.
  • A031704

    PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer (PDIGREE)
  • A151804

    Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
  • EA8171

    Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer (Phase II)
  • EAY191

    Molecular Analysis for Combination Therapy Choice (ComboMATCH)
  • NRG-GU009

    Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)
  • S1802

    Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
  • S1806

    Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
  • S2013

    Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
  • WVU011118

    Measurement of the Partial Pressure of Oxygen in Cutaneous Tumors Using Electron Paramagnetic Resonance (EPR) Oximetry